Which trial do we need? Empiric glycopeptides plus clindamycin versus oxazolidinones for suspected toxic shock and necrotizing soft-tissue infections (Toxic EGO).

Osowicki, Joshua; Hamilton, Fergus; Lee, Todd C; Marks, Michael; McCreary, Erin K; McDonald, Emily G; Ryder, Jonathan H; Tong, Steven YC; (2024) Which trial do we need? Empiric glycopeptides plus clindamycin versus oxazolidinones for suspected toxic shock and necrotizing soft-tissue infections (Toxic EGO). Clinical microbiology and infection, 30 (5). pp. 570-573. ISSN 1198-743X DOI: https://doi.org/10.1016/j.cmi.2024.02.001

Additional Information

Item Type	Article
Faculty and Department	Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
PubMed ID	38336230
Elements ID	215180
Official URL	http://dx.doi.org/10.1016/j.cmi.2024.02.001

Download

Accepted Version

Embargo Date: 6 February 2025

Restricted to: Repository staff only

Request a copy

Filename: Osowicki-etal-2024-Which-trial-do-we-need.pdf

Description: This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0